`
`CURRICULUM VITAE
`
`AARON E. MILLER, M.D.
`
`
`
`CURRENT POSITION
`
`March 2004—Present ---Medical Director, Corinne Goldsmith Dickinson Center for Multiple
`Sclerosis, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York,
`NY 10029
`
`March 2004—Present---Professor of Neurology, Icahn School of Medicine at Mount Sinai
`
`ACADEMIC APPOINTMENTS
`
`Instructor in Neurology; Albert Einstein College of Medicine, Bronx, NY; 1977-78
`
`Assistant Professor of Neurology; Albert Einstein College of Medicine; Bronx, NY 1978-1981
`
`1981--1999: Visiting Assistant Professor of Neurology, Albert Einstein College of Medicine,
`Bronx, New York
`
`1985--1992: Associate Professor of Clinical Neurology, State University of New York Health
`Sciences Center at Brooklyn
`
`1992-2003: Professor of Clinical Neurology, State University of New York Health Sciences
`Center at Brooklyn
`
`2001–2004: Clinical Professor of Neurology, Mt. Sinai School of Medicine, New York, NY
`
`2004—present: Professor of Neurology, Mt. Sinai School of Medicine, (now Icahn School of
`Medicine at Mount Sinai) New York, NY
`
`HOSPITAL APPOINTMENTS
`
`
`Attending Neurologist, Bronx Municipal Hospital Center 1978-1999
`
`Attending Neurologist, Albert Einstein College Hospital 1978-1981
`
`Director, Division of Neurology and Attending Neurologist, Maimonides Medical Center,
`Brooklyn, New York 1981—present
`
`Attending Neurologist, Kings County Hospital Center, 1981-2001
`
`Attending Neurologist, Metropolitan Jewish Geriatric Center 1981--present
`
`Attending Neurologist, Mt. Sinai Hospital (now Icahn School of Medicine at Mount Sinai), New
`York, 1999—present
`
`
`8/14/2022
`
`Hopewell EX1003
`
`1
`
`

`

`July 1, 1968--June 30, 1969
`Bronx Municipal Hospital Center
`Bronx, New York
`Straight Medicine
`
`
`EDUCATION:
`
`B.A., June, 1964, Magna cum laude, with Honors in Psychology
`Brandeis University
`Waltham, Massachusetts
`
`M.D.,
`June, 1968
`New York University School of Medicine
`New York, New York
`
`POSTDOCTORAL TRAINING:
`
`Internship:
`
`
`
`
`Junior Assistant Residency July 1, 1969--June 30, 1970
`(Medicine):
`Bronx Municipal Hospital Center
`
`Bronx, New York
`
`
`
`Neurology Residency:
`
`
`
`
`
`
`Postdoctoral Fellowship (Neurovirology and immunology):
`
`Department of Epidemiology
`Division of Infectious Disease
`(Laboratory of Dr. Neal Nathanson)
`Johns Hopkins University School of Hygiene and Public Health
`Baltimore, MD.
`July 1, 1975—June 30, 1977
`
`Department of Microbiology and Immunology
`(Laboratory of Dr. Barry Bloom)
`Albert Einstein College of Medicine
`Bronx, New York
`July 1, 1977—June 30, 1978
`
`Recipient of National Multiple Sclerosis Society Fellowship, July 1, 1976--June 30, 1978.
`
`
`July 1, 1970--June 30, 1971
`July 1, 1973--June 30, 1975
`(Chief resident, '74-'75)
`Albert Einstein College of Medicine
`Bronx, New York
`
`
`8/14/2022
`
`2
`
`

`

`
`MILITARY SERVICE
`
`Lieutenant Commander
`United States Naval Reserve
`Active duty obligation fulfilled at St. Albans Naval Hospital, Queens, New York, July, 1971--
`June, 1973
`
`CERTIFICATION
`
`National Board of Medical Examiners, July 1, 1969
`
`Certification, American Board of Internal Medicine, 1972
`
`Certification in Neurology, American Board of Psychiatry and Neurology, April, 1977.
`
`LICENSURE
`
`Medical License, New York State Dept. of Education, July, 1969—current, #104308
`
`Medical License, Maryland, 1975-77, voluntarily inactive
`
`HONORS/AWARDS/PATENTS
`
`Phi beta kappa, Mu chapter of Massachusetts, Brandeis University, 1964
`
`Alpha omega alpha, New York University School of Medicine, 1968
`
`Teacher-Investigator Award, NINCDS, July, 1979--April, 1981
`
`Fellow, American Academy of Neurology. 1985
`
`Member (elected), American Neurological Association, 1998
`
`OTHER PROFESSIONAL APPOINTMENTS
`
`Councillor, American Society for Neurologic Investigation (1982-1984)
`
`Brooklyn Neurological Society, Vice-president (1986-1988); Secretary/treasurer (1983-1986)
`
`Editorial Board, MS Quarterly (1982--2001)
`
`Editorial Board, MS Indicative Abstracts (1985--1988)
`
`Editorial Board, Multiple Sclerosis Research Reports, Demos Publications (1989--1991)
`
`Co-chairman, Professional Advisory Committee, New York Multiple Sclerosis Society (1988-
`1991; member from 1983)
`
`
`8/14/2022
`
`3
`
`

`

`National Medical Advisory Committee, National Multiple Sclerosis Society (1988--1991; 1994-
`present; Chairman 2002--2010)
`
`Council of PAC Chairmen and Clinic Directors, National Multiple Sclerosis Society (1988--
`1991)
`
`Subcommittee on Foreign Education, American Academy of Neurology (1989--1994)
`
`Chairman, Program Accreditation and Development Subcommittee (formerly known as Regional
`Education Subcommittee), American Academy of Neurology (1989-1997)
`
`Chairman, Clinical Advisory Committee, New York Multiple Sclerosis Society (1991--2004)
`
`Data and Safety Monitoring Committee, A randomized-double blind placebo-controlled trial of
`copolymer 1 in relapsing-remitting multiple sclerosis (sponsored by Teva), (1991—1994)
`
`Chairman, Professional Education Committee, National Multiple Sclerosis Society (1993--2002)
`
`President-elect, Consortium of Multiple Sclerosis Centers (1993-- 1994)
`
`Executive Board, Consortium of Multiple Sclerosis Centers (1993--1999)
`
`President, Consortium of Multiple Sclerosis Centers (1994--1995)
`
`Task Force on Clinical Outcomes Assessment, National Multiple Sclerosis Society (1994--1997)
`
`Chairman, Section on Multiple Sclerosis, American Academy of Neurology (1996-1997)
`
`Chairman, End-point committee, A randomized, double-blind placebo-controlled study of
`Avonex™ (interferon beta 1-a) in the treatment of subjects at high risk for development of
`multiple sclerosis following the first onset of an isolated demyelinating event. (Biogen,
`Lawrence Jacobs, PI) (1996-2000)
`
`Member, Annual Meeting Management Committee, American Academy of Neurology (1997—
`2003)
`
`Chairman, Annual Meeting Subcommittee, American Academy of Neurology (1997-2003)
`
`Co-chairman, Education Committee, American Academy of Neurology (1997-2003)
`
`Member, Research Programs Advisory Committee, National Multiple Sclerosis Society (2003—
`2020)
`
`Member, Steering Committee, A double-blind, placebo-controlled, parallel group safety study of
`natalizumab in combination with glatiramer acetate in subjects with relapsing-remitting multiple
`sclerosis. (Biogen, Inc.) (2003—2005)
`
`Member, Board of Directors, National Multiple Sclerosis Society (2003—2017)
`
`
`8/14/2022
`
`4
`
`

`

`Editor, Continuum. American Academy of Neurology (2003—2012). (Continuum is the
`bimonthly continuing education journal of the AAN)
`
`Member, American Academy of Neurology/American Board of Psychiatry and Neurology
`Leadership Committee (2003—present)
`
`Member, Publications Committee, American Academy of Neurology (2003—present)
`
`Member, Steering Committee for development of Teriflunomide as treatment for Multiple
`Sclerosis; Sanofi-Aventis, 2004—2013
`
`Member, Data Monitoring and Safety Committee for Safety and Effectiveness of Two Doses of
`ABT-874 as Compared to Placebo in Subjects with Multiple Sclerosis, Abbott Laboratories,
`2006--2008
`
`Member, Data Monitoring and Safety Committee for Study of SB-683699 Compared to Placebo
`in Subjects with Relapsing-Remitting Multiple Sclerosis, Glaxo Smith Kline, 2007—2012
`
`Chairman, Data Monitoring and Safety Committee for A Study of Safety and Efficacy of ONO-
`4641 in Patients with Relapsing-Remitting Multiple Sclerosis, ONO, 2009—2013.
`
`Chairman, Data Monitoring and Safety Committee for A 12 Week Safety Evaluation of Oral CS-
`0777 in Multiple Sclerosis Patients, Daiichi-Sankyo, 2009—2011
`
`Member, Board of Directors, American Academy of Neurology 2009—2013
`
`Secretary, Board of Directors and member of Executive Committee of the Board, American
`Academy of Neurology, 2013--2017
`
`Chairman, Editors-in-chief Committee, American Academy of Neurology (2009—2011)
`
`Member, Education Committee, World Federation of Neurology, 2010—2012
`
`Member, Scientific Working Group, advising Canadian Institute of Health Research on Chronic
`Cerebrospinal Venous Insufficiency, 2010--current
`
`Member, Data Monitoring and Safety Committee for Phase 3 trial of ofatumumab in relapsing
`multiple sclerosis, Glaxo Smith Kline, 2012—2014
`
`Member, Publications Committee, World Federation of Neurology, 2012—2014
`
`Editor, Continuum Audio, a joint venture of Audio Digest and American Academy of
`Neurology, 2011—present
`
`Section Editor (Therapy), Multiple Sclerosis and Related Disorders, 2011—present
`
`Participant, Advisory Panel on Costs of Medications for Multiple Sclerosis, National Multiple
`Sclerosis Society, March 2012
`
`
`8/14/2022
`
`5
`
`

`

`Member, Diversity Leadership Work Group, American Academy of Neurology, 2015-2017
`
`Member, Pharmacy Quality Alliance MS Treatment and Monitoring Task Force, 2015-2017
`
`Member, Leadership Committee, American Academy of Neurology, 2017—2021
`
`Member, Fast Forward Board of Managers, National Multiple Sclerosis Society, 2017-present
`
`Member, Publications Committee, American Academy of Neurology, 2011-2021
`
`Chairman, National Medical Advisory Committee, National Multiple Sclerosis Society, 2018—
`2020
`
`Member, National Medical Advisory Committee, National Multiple Sclerosis Society, 2021—
`present
`
`Member, Search Committee for Editor of Continuum, American Academy of Neurology, 2021
`
`Member, Scientific Advisory Committee (formerly Research Programs Advisory Committee),
`National Multiple Sclerosis Society, 2021--current
`
`
`TEACHING ACTIVITIES
`
`Attending rounds for medical students from Mt. Sinai, SUNY at Brooklyn, and other medical
`students conducted weekly at Maimonides Medical Center 1981—current (schedule has
`changed over the years from one month at a time to weekly rounds through the year)
`
`Brain and Behavior, Small Group Leader, Mount Sinai (2nd year course)—2006—current
`
`Attending Rounds, Ward Service, Mount Sinai School of Medicine, 1 month/year; 2004-current
`
`Morning Report for Residents and Students, weekly, Mount Sinai School of Medicine, 2005—
`current
`
`Supervisor, Multiple Sclerosis Fellows (up to 6); Corinne Goldsmith Dickinson Center for
`Multiple Sclerosis, Mount Sinai School of Medicine
`
`OTHER ICAHN SCHOOL OF MEDICINE ACTIVITIES
`
`Department of Neurology Representative to Faculty Council, 2010—present
`
`Department of Neurology, Vice-Chair for Education, 2017--present
`
`GRANT SUPPORT
`
`Past Grants (Partial list—information about additional pharmaceutical grants in 1980s not
`available)
`
`
`8/14/2022
`
`6
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7/79—4/81
`terminated by
`(voluntarily
`grantee because of change of
`position)
`Paid full salary (exact amount
`not available)
`
`5/89—6/95
`$257,136
`
`12/91—11/93
`$116,450
`
`1/92—1/93
`$7,500
`
`
`
`
`
`
`
`
`
`11/92—1/95
`$80,297
`
`4/93—10/96
`$110,209
`
`7/94—9/97
`$158,439
`
`10/94—4/99
`$132,827
`
`8/1/95—7/31/96
`$25,000
`
`
`
`NINDS
`Teacher-Investigator Development Award
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Forest Laboratories
`The efficacy of extended-release oral physostigmine
`in Alzheimer’s disease and senile dementia of the
`Alzheimer’s type.
`Site principal investigator
`
`
`
`Dupont-Merck
`A randomized, placebo-controlled study of
`Dup 996 (linopirdine), 90 and 120 mg daily
`in patients with mild to moderate dementia of
`the Alzheimer’s type.
`Site principal investigator
`
`Maimonides Research and Development Foundation
`Botulinum toxin therapy of tremor in multiple sclerosis
`Principal investigator
`
`
`
`
`
`Glaxo
`Ondansetron in the study of dementia
`Site principal investigator
`
`
`
`
`
`Organon
`Trial of Organon 10172 in acute stroke treatment
`Site principal investigator
`
`
`
`
`AutoImmune, Inc.
`A double-blind, placebo-controlled, multi-center
`study of oral myelin (Myloral™) in the treatment
`of early relapsing-remitting multiple sclerosis.
`Site principal investigator
`
`
`
`
`NINDS
`Warfarin antiplatelet recurrent stroke study
`Site principal investigator
`
`National Multiple Sclerosis Society
`A multi-center, randomized, double-blind
`placebo-controlled trial of influenza
`immunization in multiple sclerosis
`Principal Investigator
`
`
`
`
`
`
`8/14/2022
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7
`
`

`

`
`
`
`
`
`Ciba-Geigy
`Selfotel protocol 07 M8535Q—A multicenter, randomized,
`double-blind, parallel trial comparing the efficacy and
`safety of a single IV dose (1.5 mg/kg) of Selfotel
`with placebo in patients age 40-85 with acute
`ischemic stroke.
`Site principal investigator
`
`
`
`
`
`
`
`Pharmacia, Inc.
`
`Linomide—A randomized, double-blind, placebo-
`controlled, phase 3 studfy of roquinimex (Linomide®)
`in relapsing-remitting and secondary progressive
`multiple sclerosis
`Site principal investigator
`
`
`
`
`Berlex
`Phase III, double-masked, placebo-controlled
`study to evaluate the safety and efficacy of two
`doses of Betaseron in patients with secondary
`progressive multiple sclerosis.
`Site principal investigator
`
`
`Alzheimer’s Disease Cooperative Study Group
`Idebenone—A randomized, double-blind, placebo-
`controlled twelve-month safety and efficacy trial of
`120, 240, and 360 mg tid of idebenone (CV-2619)
`in patients with probable Alzheimer’s disease
`Site principal investigator
`
`
`
`
`
`
`Pfizer
`A global randomized, double-blind study (with open-label
`extension to evaluate the efficacy and safety of Viagra™
`(sildenafil) in multiple sclerosis patients with
`erectile dysfunction
`Site principal investigator
`
`
`
`
`ICOS
`Multiple sclerosis multidose protocol AMS05
`Site principal investigator
`
`
`Elan Pharmaceuticals
`Tizanidine MR study, AN021-302
`Site principal investigator
`
`
`Alzheimer’s Disease Cooperative Study Group
`A multicenter, randomized, double-blind,
`
`placebo-controlled trial to evaluate the safety
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8/14/2022
`
`8/95—4/96
`$24,294
`
`9/95—6/98
`$210,015
`
`5/96-12/99
`$402,807
`
`7/97—3/00
`$346,132
`
`1/98—6/99
`$10,290
`
`6/98—12/99
`$24,017
`
`2/99—5/00
`$27,939
`
`
`
`8/99—1/04
`$23,905
`
`
`
`8
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`12/99—12/03
`$120,432
`
`3/00—4/01
`$72,874
`
`1/01—-7/02
`$17,380
`
`and efficacy of vitamin C and donepezil
`hydrochloride (Aricept) to delay clinical
`progression from mild cognitive impairment
`(MCI) to Alzheimer’s disease.
`Site principal investigator
`
`
`
`
`
`
`
`
`Aentis Pharmaceuticals
`A multi-national, multi-center, double-blind,
`placebo controlled study to evaluate the efficacy,
`tolerability and safety of glatiramer acetate for
`injection in Primary Progressive Multiple Sclerosis
`patients.
`
`Site principal investigator
`
`
`
`
`
`
`
`Cromedica
`Multicenter, randomized, double-blind, placebo-controlled
`study to evaluate Neotrofin™ (AIT-082) in patients with
`probable Alzheimer’s disease of mild to moderate
`severity
`Site principal investigator
`
`
`
`
`
`Teva Neuroscience
`CORAL—A multinational, multicenter randomized,
`double-blind, placebo-controlled study to evaluate
`the efficacy, tolerability, and safety of 2 doses (5 mg and
`50 mg) glatiramer acetate orally administered in relapsing-
`remitting multiple sclerosis.
`Site principal investigator
`
`
`
`
`
`
`Pfizer
`A 12-week, multicenter, randomized, double-blind, placebo-
`controlled evaluation of the efficacy and safety of donepezil
`hydrochloride (E2020) in the treatment of cognitive
`impairment in patients with multiple sclerosis.
`Site principal investigator
`
`2/02—1/03
`
`
`
`
`
`Serono
`An open label, randomized, multicenter comparative study $81,098
`of Rebif 44 mcg administered three times per week by
`subcutaneous injection compared with Avonex 30 mcg
`administered once per week by intramuscular injection in
`the treatment of relapsing-remitting multiple sclerosis.
`Site principal investigator
`
`Serono
`
`4/00—4/02
`$189,557
`
`
`
`
`
`
`
`
`
`
`
`2/02—9/02
`
`8/14/2022
`
`9
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A randomized, multicenter, parallel group, open-label study
`comparing the tolerability of Rebif injection with and
`without the use of Rebiject™ Mini in relapsing remitting
`MS patients.
`Site principal investigator
`
`
`
`
`
`
`
`
`Biogen, Inc.
`A randomized, double-blind, placebo-controlled,
`parallel-group, multicenter study to determine the
`safety and efficacy of natlizumab, when added
`to Avonex (Interferon beta-1a), in subjects with
`relapsing-remitting MS (SENTINEL).
`Site principal investigator.
`
`
`
`
`
`
`Immunex
`
`Prospective open-label tolerability and safety monitoring
`study of Novantrone (mitoxantrone for injection, concentrate) in
`a selected cohort of MS patients.
`Site principal investigator
`
`
`
`
`Sanofi-Synthelabo Research
`
`Clopidogrel for high atherothrombotic risk and
`ischemic stabilization, management, and avoidance
`(CHARISMA).
`Site principal investigator.
`
`
`
`
`
`Acorda Therapeutics, Inc.
`Double-blind, placebo-controlled, 20-week parallel
`group study to evaluate safety, tolerability, and activity
`of oral fampridine-SR in subjects with multiple sclerosis.
`Site principal investigator.
`
`
`
`
`
`Biogen
`A double-blind, randomized, placebo-controlled, parallel
`group design safety study of natalizumab in
`
`combination with glatiramer acetate in subjects with
`relapsing-remitting multiple sclerosis.
`Site principal investigator
`
`
`
`NIH/ Immune Tolerance Network (ITN)
`
`A randomized, double-blind, placebo-controlled,
`Multi-center study to evaluate the efficacy and safety
`Of atorvastatin in patients with clinically isolated
`Syndrome and high risk conversion to MS (STAYCIS)
`Site principal investigator
`
`
`
`
`
`
`
`
`
`
`8/14/2022
`
`$20,500
`
`4/02—2/05
`$19,000 per pt
`(7 pts enrolled)
`
`6/02—12/03
`$2,425
`
`1/03—05
`$4,025 per patient
`(5 patients enrolled)
`
`2/03—1/06
`$8,250 per patient
`(9 patients enrolled)
`
`
`4/03—2/05
`$12,600 per patient
`(5 patients enrolled)
`
`
`
`3/04—2/10
`$36,641 per patient
`
`
`
`
`
`
`
`
`
`
`
`
`
`10
`
`

`

`
`
`
`
`
`Acorda Therapeutics
`Double-Blind, Placebo-Controlled, 21-Week, Parallel
`Group Study to Evaluate Safety and Efficacy of Oral
`Fampridine-SR (10 mg BID) in Subjects with Multiple
`Sclerosis MS-F203
`Site sub-investigator
`
`
`
`
`
`
`
`
`Genentech
`A Phase II/III, Randomized, Double-Blind, Parallel-Group,
`Placebo-Controlled, Multi-Center Study to evaluate the
`
`Safety and Efficacy of Rituximab in Adults with
`Primary Progressive Multiple Sclerosis: U2786g
`Site principal investigator
`
`
`
`
`
`Teva Neuroscience
`A multi-center, randomized, double-blind, placebo
`controlled study assessing the add-on effect of oral
`steroids in relapsing remitting multiple sclerosis
`subjects treated with glatiramer acetate (GA) (ASSERT).
`Site principal investigator
`
`
`
`
`
`
`Acorda Therapeutics, Inc.
`Double-Blind, Placebo-Controlled, Parallel Group Study to
`Evaluate Safety and Efficacy of Oral Fampridine-SR
`
`(10 mg b.i.d.) in patients with Multiple Sclerosis MSF204
`Site sub-investigator
`
`
`
`Novartis
`A Randomized Placebo-Controlled Trial
`of Fingolimod in PPMS (INFORMS)
`Site PI
`
`
`
`Biogen
`A Randomized Placebo-Controlled Trial of
`Natalizumab on Reducing Disability Progression in SPMS
`(ASCEND trial)
`Site PI
`
`
`
`
`
`
`
`Questcor
`With Acute Relapses Failing IV Methylprednisolone
`PI
`
`
`
`
`
`Biogen
`An Open-Label, Multicenter Study in Subjects with
`Relapsing-Remitting Multiple Sclerosis to Evaluate the
`Safety of 240 mg BG00012 TID Administered as Add-On
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8/14/2022
`
`12/04—2/08
`$6,925 per patient
`
`6/04—9/09
`$34,823 per patient
`
`
`11/05—3/10
`$21,317 per patient
`
`
`
`
`
`
`04/07—1/09
`$8,248 per patient
`
`
`2008-2014
`
`2011-2016
`
`2013-2018
`
`2010—2012
`
`
`
`
`11
`
`

`

`Therapy to Beta Interferons (IFNβ) or Glatiramer Acetate (GA)
`Site principal investigator
`
`
`Multicenter, Double-blind, Randomized, Parallel-group,
`and Safety of Daclizumab High Yield Process (DAC HYP)
`versus Avonex® (Interferon β-1a) in Patients with
`Relapsing-Remitting Multiple Sclerosis
`Site sub-investigator
`
`
`
`
`
`Novartis
`A double-blind, randomized, multi-center, placebo
`Controlled, parallel-group study comparing the
`
`orally once daily versus placebo in patients with PPMS
`Site principal investigator
`
`
`
`
`
`
`
`Sanofi-Aventis
`
`An international, multi-center, randomized, double-blind,
`
`placebo-controlled, parallel group study to evaluate the
`efficacy and safety of two year treatment with teriflunomide
`7 mg once daily and 14 mg once daily versus placebo in
`patients with a first clinical episode suggestive of
`multiple sclerosis.
`Site sub-investigator
`
`
`
`
`
`
`Genzyme
`
`A Phase 3, Randomized, Rater- and Dose-Blinded Study
`
`Comparing Two Annual Cycles of Intravenous Low- and
`High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous
`Interferon Beta‑1a (Rebifâ) in Patients with
`Relapsing‑Remitting Multiple Sclerosis Who Have Relapsed
`On Therapy
`Site sub-investigator
`
`
`
`
`
`
`Acorda Therapeutics, Inc.
`
`Open Label Extension Study to Evaluate the Safety,
`Tolerability and Activity of Oral Fampridine-SR in Patients
`with Multiple Sclerosis who Participated in the MS-F204 Trial
`204 EXT
`Site sub-investigator
`
`
`
`
`
`Novartis
`A 24 month, double-blind, randomized, double-blind,
`Parallel group study comparing efficacy and safety of
`FTY7201.25mg and 0.5mg administered orally once daily
`versus placebo in patients with RRMS (FREEDOMS II)
`Site principal investigator
`
`Acorda Therapeutics, Inc.
`
`
`
`
`
`
`
`
`
`2010-2014
`
`2/09—present
`$56,255 per patient
`
`
`7/08—closedt
`$33,028 per patient
`
`
`
`3/08—closed
`$30,489 per patient
`
`1/08—closed
`$8,248 per patient
`
`
`9/06—closed
`$42,937 per patient
`
`
`11/05—closed
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`8/14/2022
`
`12
`
`

`

`
`
`
`
`
`Open-Label Extension Study to Evaluate the Safety,
`Tolerability and Activity of Oral Fampridine-SR in Subjects
`with Multiple Sclerosis who Participated in the MS-F203 Trial
`203 EXT
`Site sub-investigator
`
`
`
`
`
`
`Acorda Therapeutics, Inc.
`
`Open-Label Extension Study to Evaluate the Safety,
`Tolerability and Activity of Oral Fampridine-SR in Subjects
`with Multiple Sclerosis 202 EXT
`Site sub-investigator
`
`National Multiple Sclerosis Society (Fred Lublin, PI)
`Oral megadose corticosteroid therapy of acute
`
`exacerbations of multiple sclerosis (OMEGA).
`
`Site principal investigator.
`
`New York State Department of Health and Jacobs Foundation
`The establishment of a patient registry and initiation of related
`Projects of the New York State Multiple Sclerosis Consortium.
`Site principal investigator
`
`
`
`
`
`Current Grants
`
`
`
`
`
`
`
`
`NINDS
`Mount Sinai Network of Excellence in Neuroscience Trials
`(NeuroNext)
`Site Co-Principal Investigator
`
`Johns Hopkins University School of Medicine (PCORI Funded)
`Traditional vs Early Aggressive Therapy for Multiple Sclerosis
`(TREAT-MS) Trial
`Site principal investigator
`
`
`
`
`
`Immune Tolerance Network (NIH)
`A Multicenter Randomized Controlled Trial of Best Available
`Therapy versus Autologous Hematopoietic Stem Cell Transplant
`For Treatment-Resistant Relapsing Multiple Sclerosis
`(BEAT-MS)
`
`Site Principal investigator
`
`
`
`University of Colorado (PCORI Funded)
`Discontinuation of Disease Modifying Therapy (DMT) in
`Multiple Sclerosis (MS) (DISCO-MS)
`Site Principal Investigator
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$6,925 per patient
`
`
`3/04—closed
`$9,112 per patient
`
`8/1/03--closed
`$3,060 per patient
`(up to $49,560)
`
`7/96--2005
`
`2018-present
`$339,000 1st year
`
`2019—present
`
`2020--present
`
`2017—Present
`
`8/14/2022
`
`13
`
`

`

`
`
`
`
`
`
`2017-present
`
`2015-present
`
`2012-present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Med Day
`Effect of MS1003 in Progressive Multiple Sclerosis:
`A Randomized, Double-Blind, Placebo-Controlled Study
`Site PI
`
`
`
`
`
`
`
`Roche
`Randomized Study of Ocrelizumab Compared to Placebo
`For Primary Progressive MS (ORATORIO Extension
`Trial)
`Site PI
`
`
`
`
`
`
`
`
`
`
`\Novartis
`A Randomized Placebo-Controlled Trial of Siponimod
`In Secondary Progressive MS (EXPAND trial)
`Site PI (leading North American recruiter)
`Site PI in EXPAND-Extension Trial
`
`
`
`PUBLICATIONS
`
` Original peer-reviewed articles
`
`
`
`1. Miller A and Nathanson N: Rabies: Recent advances in pathogenesis and control.
`Annals of Neurol., 2: 511-519, 1977.
`
`
`2. Georgsson G, Petursson G, Miller A et al: Experimental visna in fetal Icelandic sheep.
`J. Comp. Pathol. 88: 597-605, 1978.
`
`3. Nathanson N and Miller A: Epidemiology of multiple sclerosis: Critique of the
`evidence for a viral etiology. Am. J. Epidemiol., 104: 451-461, 1978.
`
`
`
`
`
`4. Miller A, Morse HC, III, Winkelstein JA and Nathanson N: The role of antibody in
`recovery from experimental rabies: 1. Effect of depletion of B and T cells. J. Immunol.
`121: 321-326, 1978.
`
`
` 5. Nathanson N, Petursson G, Georgsson G, Palsson P, Martin J, and
` Miller A: Pathogenesis of visna IV. Spinal fluid studies. J. Neurol. Pathol. Exp.
` 1979. Neurol. 38: 197-208,
`
` 6. Miller A: Selective decline in cellular immune response to varicella-zoster in the
` elderly. Neurology 30: 582-587, 1980.
`
` 7. Neighbour PA, Miller AE, and Bloom BR: Interferon responses of leukocytes in
`
`8/14/2022
`
`14
`
`

`

` multiple sclerosis. Neurology 31: 561-566, 1981.
`
` 8. Miller AE, Neighbour PA, Katzman R, Aronson M, and Lipkowitz R:
` Immunological studies in senile dementia of the Alzheimer type: evidence for
` enhanced suppressor cell activity. Annals of Neurol. 10:506-510, 1981.
`
` 9. Bornstein MB, Miller A, Teitelbaum D, et al: Multiple sclerosis: Trials of a
` synthetic peptide. Ann. Neurol. 11:317-319,1982.
`
` 10. Miller AE: Cessation of stuttering with progressive multiple sclerosis. Neurology .
` 35: 1341-1343, 1985
`
` 11. Bornstein MB, Miller A, Slagle S. et al: Copolymer 1 in exacerbating-remitting
` multiple sclerosis. New England J. Med. 317:408-414, 1987.
`
` 12. McDowell F, Miller A, Namerow N, and Scheinberg L: The symptomatic
` management of multiple sclerosis. J. Neurorehab. 2:137-139, 1988.
`
` 13. Merriam AE, Hegarty A, and Miller A: A proposed etiology for psychotic
` symptoms in white matter dementia. Neuropsychiatry, neuropsychology and
` behavioral neurology. 2:225-228, 1989.
`
`14. Hegarty A, Miller A, and Merriam AE: The mental disabilities of metachromatic
` leukodystrophy: Implications concerning the differentiation of cortical, subcortical
` gray, and white matter dementias. Neuropsychiatry, neuropsychology, and
` behavioral neurology: 3: 217-219, 1990.
`
`15. Ofosu-Appiah W, Mokhtarian F, Miller A et al. Characterization of in vivo-activated
` T cell clones from peripheral blood of multiple sclerosis patients. Clin immunol and
` immunopathol 58: 46-55, 1991.
`
`16. Hriso E, Masdeu JC, Miller A. Monocular elevation weakness and ptosis: An
` oculomotor fasciculus syndrome? J. Clin. Neuroopthal. 11:111-113, 1991.
`
`17. Bornstein MB, Miller A, Slagle S et al. A placebo-controlled, double-blind,
` randomized, two-center pilot trial of Cop 1 in chronic progressive multiple sclerosis.
` Neurology 41:533-539, 1991.
`
`18. Shirazian D, Mokhtarian F, Herzlich BC, Miller AE, Grob D. Presence of cross-
` reactive antibodies to HTLV-1 and absence of antigens in patients with multiple
` sclerosis. J Lab Clin Med 122:252-259, 1993.
`
`19. Keilson MJ, Drexler ED, Miller AE, Bruining K. Central pontine myelinolysis with
` complete recovery. J Neuroimag 1994;4:47-48.
`
`20. Mokhtarian F, Shi Y, Shirazian D, Morgante L, Miller A, Grob D. Defective
` production of anti-inflammatory cytokine, TGF-B by T cell lines of patients with
` active multiple sclerosis. J. Immunol., 1994, 152:6003-6010.
`
`
`8/14/2022
`
`15
`
`

`

`21. Krupp LB, Coyle PK, Doscher C, Miller A, Cross A, Jandorf L, Halper J, Johnson B,
` Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: Results of a double
` blind randomized parallel trial of amantadine, pemoline, and placebo. Neurology,
` 1995;45:1956-1961.
`
`
`22. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A,
` Petkau J, Rao S, Reingod S, Syndulko K, Thompson A, Wallenberg J, Weinshenker
` B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol
` 1996:40:469-479.
`
`23. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher
` CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, LaRocca N, Lopez S.
` A multi-center, randomized, double-blind placebo-controlled trial of influenza
` immunization in multiple sclerosis. Neurology 1997; 48:312-314.
`
`24. Mokhtarian F, Shirazian D, Morgante L, Miller A, Grob D, Lichstein E. Influenza
` virus vaccination of patients with multiple sclerosis. Multiple sclerosis 1997;3:243-
` 247.
`
`25. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A,
` Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Miller
` AE, Perel A, Smith CR, Snyder DH and the New York State Multiple Sclerosis
` Consortium. A profile of multiple sclerosis: The New York State Multiple Sclerosis
` Consortium. Multiple Sclerosis 1999;5:369-376.
`
`26. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K,
` Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao
` SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis
` functional composite as a clinical trial outcome measure. Brain 1999;122:871-882.
`
`27. Schwid S, Goodman A, Apatoff B, Coyle P, Jacobs L, Krupp L, Miller A, Wende K,
` Brownscheidle, and the New York State Multiple Sclerosis Consortium. Are
` quantitative functional measures more sensitive to worsening MS than traditional
` measures? Neurology 2000;55:1901-1903
`
`28. Cook SD, Quinless JR, Jotkowitz A, Beaton P, and the Neurtralizing Antibody Study Group
` (Miller A—member). Neurology 2001;57:1080-1084.
`
`29. Pedley TA, Swift TR, Miller A, Fahn S. Pharmaceutical industry support of the AAN
` Annual Meeting. Policies and Violations. Neurology 2002;58:519-521.
`
`30. Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis—current
` practice and future directions. J Rehabil Res Dev 2002; 39:273-285
`
`31. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff
` BR, Blitz KM, Coyle PK, Grontera AT, Goodman AD, Gottesman MH, Holub HJ,
`Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R,
`Granger CV, Greenberg SJ, Jubelt B, Krupp0 L, Munschauer FE, Rubin D, Schwid S,
`Smiroldo J, New York State Multiple Sclerosis Consortium. Multiple sclerosis characteristics
`
`8/14/2022
`
`16
`
`

`

`in African American patients in the New York State Multiple Sclerosis Consortium. Mult
`Scler 2003; 9:293-298.
`
`32. Boneschi FM, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni
` G, Comi G, Filippi M. Effects of glatiramer acetate on relapse rate and accumulated
` disability in multiple sclerosis: meta-analysis of three double-blind, randomized,
` placebo-controlled clinical trials. Mult. Scler. 2003; 9:349-355.
`
`33. Miller AE, Coyle PK. Clinical features of multiple sclerosis. Continuum 2004;10:38-73.
`
`34. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon
` beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS:
` results from a 3-year controlled study. Neurology 2004; 63:1788-1795.
`
`35. Miller AE. Glatiramer acetate in the treatment of multiple sclerosis. Neurol Clin 2005;
` 215-231.
`
`36. Miller A. Ethical issues in MS clinical trials. Mult Scler 2005;11:97-98.
`
`37. Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo
`L, Kadosh S, Ladkani D; PROMiSe Trial Study Group. Glatiramer acetate in primary
`progressive multiple sclerosis: results of a multinational,